Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06020807 · ClinicalTrials.gov registry record
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
A clinical trial, sponsored by Nucleix.
- Completed
- Registry status
- 168
- Enrollment target
NCT06020807 is a clinical trial that has completed, run by Nucleix. The registered enrollment target is 168 participants.
The verdict
NCT06020807 has completed, sponsored by Nucleix.
- COMPLETED
- Registry status
- 168 participants
- Enrollment target
Study Summary
This is a prospective study to establish the analytical specificity of Bladder EpiCheck test in urine samples from healthy population and urology patients without prior history or evidence of bladder cancer.
Interventions
- DIAGNOSTIC_TEST Bladder EpiCheck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2020-01-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06020807
The ClinicalTrials.gov registry entry for NCT06020807 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nucleix, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bladder EpiCheck is the first listed.
NCT06020807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06020807 about?
NCT06020807 is a clinical study titled "Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer". This is a prospective study to establish the analytical specificity of Bladder EpiCheck test in urine samples from healthy population and urology patients without prior history or evidence of bladder cancer.
What is the current status of trial NCT06020807?
This trial is currently completed. The enrollment target is 168 participants. The study started on 2019-09-05. Estimated completion is 2020-01-08.
What interventions are being tested in trial NCT06020807?
The interventions under investigation include: Bladder EpiCheck (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06020807?
This trial is sponsored by Nucleix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.